Last checked at 6 Dec 2016 07:00
THIS DOCUMENT (AND THE INFORMATION CONTAINED HEREIN) IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WITHIN, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), CANADA, AUSTRALIA, JAPAN, NEW ZEALAND AND SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.
This document does not constitute an offer of, or a solicitation to subscribe for or purchase, any securities in any jurisdiction in which such offer or solicitation is unlawful or to any person to whom it is unlawful to make such offer or solicitation, including in the United States.
Securities may not be offered or sold in the United States absent registration under the United States Securities Act of 1933, as amended (the "Securities Act"), or an exemption from, or in a transaction not subject to, registration. The Company has not and does not intend to register any securities under the Securities Act, and does not intend to offer any securities to the public in the United States unless registered under the Securities Act or an exemption from such registration is available. No public offering of securities of the Company is being made in the United States.
No communication or information relating to the issue and offering of securities may be disseminated to the public in jurisdictions other than the UK where prior registration or approval is required for that purpose. No action has been taken that would permit an offer of securities in any jurisdiction where action for that purpose is required, other than in the UK.
6 December 2016
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
ADMISSION TO AIM
AND FIRST DAY OF DEALINGS
Oxford BioDynamics Plc (AIM: OBD) is pleased to announce the admission from 8:00am today of its ordinary shares to trading on AIM, a market operated by the London Stock Exchange plc ("Admission") and the commencement of dealings in its Ordinary Shares under the TIDM "OBD" and with ISIN number GB00BD5H8572.
The Admission Document, along with the information required by AIM Rule 26, is available on the Company's website, www.oxfordbiodynamics.com.
Summary of the Placing
§ The Placing, which was oversubscribed, has raised gross proceeds of £20.0 million, of which £7.1 million (before expenses) was allocated to the Company.
§ The number of Ordinary Shares in issue on Admission will be 86,098,228, giving the Company a market capitalisation of £136.0 million at the Placing Price of 158 pence per share.
The total number of voting rights in the Company with effect from today is 86,098,228 Ordinary Shares. This figure may be used by shareholders as the denominator for calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.
For further details contact:
Oxford BioDynamics Plc +44 (0)1865 518910
Christian Hoyer Millar, CEO
Katie Long, CFO
FTI Consulting +44 (0)20 3727 1000
Financial Public Relations Advisor
Julia Phillips
Brett Pollard
Natalie Garland-Collins
Matthew Moss
Stifel Nicolaus Europe Limited +44 (0)20 7710 7600
Nominated Advisor and Broker
David Arch
Jonathan Senior
Peter Lees
Ben Maddison
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a revenue‐generating biotechnology company focused on the discovery and development of novel epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.
The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.
In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.
Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.